<DOC>
	<DOCNO>NCT02321644</DOCNO>
	<brief_summary>This two-part , phase 1 study evaluate pharmacokinetics pharmacodynamics multiple dos CC-90001 effect food formulation pharmacokinetics single dose CC-90001 healthy subject . Part 1 involves exposure subject minimum amount UV-B light cause minimally perceptible skin reddening . This take place dosing ( baseline ) 3 time increase dos CC-90001 . Punch biopsy expose area take assessed c-Jun terminal kinase activity . Part 2 involve evaluation change pharmacokinetics 2 formulation CC-90001 administer fasted state high-fat meal .</brief_summary>
	<brief_title>Effect UV Exposure PD Multiple Doses CC-90001 Pilot Food Effect Study</brief_title>
	<detailed_description>Part 1 open-label , multiple-dose , 3-period , fixed-sequence study , evaluate effect CC-90001 JNK activity follow UV irradiation . On first day prior dose ( baseline ) , 6th day dose period ( Days 6 , 12 , 18 ) , twice MED intensity UV light administer delineated site subject ' buttock . The irradiation baseline ( Day -1 ) administer approximately time irradiation schedule Days 6 , 12 , 18 , 2 hour post dose . Eight hour UV irradiation , skin punch biopsy take UV exposure site . The end confinement Day 19 . The follow-up visit occur 7-10 day ( ie , Day 25 Day 28 ) follow last dose Period 3 . An early termination ( ET ) visit occur within 10 day day discontinuation . The MED determine within 10 day dose Period 1 . All subject receive follow dos CC-90001 fix sequence : Treatment A : 60 mg CC-90001 AIC , QD x 6 day ; Treatment B : 160 mg CC-90001 AIC , QD x 6 day ; Treatment C : 400 mg CC-90001 AIC , QD x 6 day . Subjects confine unit Day -1 discharge Day 19 safety assessment . In Part 2 subject assign randomly one three dose sequence receive one follow dose regimen : - Treatment D : 2 x 100 mg CC-90001 AIC , single oral dose administer fasted condition . - Treatment E : 1 x 200 mg CC-90001 [ formulate tablet ( ) ] single oral dose administer fasted condition - Treatment F : 1 x 200 mg CC-90001 [ formulate tablet ( ) ] single oral dose administer fed condition ( standard high fat breakfast ) .</detailed_description>
	<criteria>1 . Must understand voluntarily sign write Informed Consent Document ( ICD ) prior studyrelated assessments/procedures perform 2 . Must able communicate Investigator understand adhere study visit schedule protocol requirement 3 . Must male female* , age 18 year age 65 year age ( inclusive ) time sign ICD * Women childbearing potential ( WCBP ) *must agree ongoing pregnancy test course study , end study . This apply even subject practice true abstinence heterosexual contact 1 . The female subject must either commit true abstinence** heterosexual contact ( must review monthly basis ) agree use , able comply , 2 highly effective contraception without interruption , 28 day prior start study drug , study therapy ( include dose interruption ) , least 28 day discontinuation study drug 2 . Females childbearing potential either surgically sterilize least 6 month prior screen ( hysterectomy bilateral tubal ligation ) postmenopausal ( defined 24 month menses prior Screening , AND plasma follicle stimulate hormone ( FSH ) &gt; 40 IU/L screening ) . Documentation require case tubal ligation 4 . Males must practice true abstinence** agree use condom ( latex condom recommend ) sexual contact pregnant female WCBP study drug , participate study , dose interruption least 28 day follow study drug discontinuation , even undergone successful vasectomy ** True abstinence acceptable line prefer usual lifestyle subject [ Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] 5 . Has body mass index ( BMI = weight [ kg ] / ( height [ m2 ] ) 18 33 kg/m2 ( inclusive ) 6 . Must healthy determine Investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead ECGs Must afebrile ( febrile define ≥ 38 °C 100.3° Fahrenheit ) Systolic blood pressure must range 80 140 mmHg , diastolic blood pressure must range 40 90 mmHg , pulse rate must range 40 110 bpm QTcF value ≤ 430 msec male subject ≤ 450 msec female subject . An ECG may repeat 3 time determine subject eligibility 7 . Additional criterion Part 1 : 1 . Must Fitzpatrick skin type I II 2 . Must valid MED obtain within 10 day prior dose 1 . History ( ie , within 3 year ) clinically significant neurological , gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , endocrine , hematological , dermatological , psychological , major disorder 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study , confound ability interpret data study 3 . Use prescribed systemic topical medication , include vaccine , within 30 day first dose 4 . Use nonprescribed systemic topical medication ( include herbal medicine ) within 14 day first dose administration ( exception vitamin/mineral supplement ) 5 . Use metabolic enzyme inhibitor inducer ( ie , CYP3A inducers inhibitor St. John 's wort ) within 30 day first dose administration . The University Indiana `` Cytochrome P450 Drug Interaction Table '' use determine inhibitor and/or inducer CYP 3A4 ( http : //medicine.iupui.edu/clinpharm/ddis/table/aspx ) 6 . Presence surgical medical condition possibly affect drug absorption , distribution , metabolism excretion ( ADME ) , eg , bariatric procedure a. Appendectomy cholecystectomy acceptable 7 . Donated blood plasma within 8 week first dose administration 8 . History drug abuse ( define current version Diagnostic Statistical Manual [ DSM ] ) within 2 year dose , positive drug screen test reflect consumption illicit drug ) 9 . History alcohol abuse ( define current version DSM ) within 2 year dose , positive alcohol screen 10 . Known serum hepatitis know carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) , positive result test HIV antibodies Screening 11 . Exposed investigational drug ( new chemical entity ) within 30 day precede first dose administration , 5 halflives investigational drug , know ( whichever longer ) 12 . Smoke 10 cigarette per day , equivalent tobacco product ( self report ) 13 . Subject history multiple drug allergy ( ie , 2 ) Additional Exclusion Criteria Subjects Part 1 Only : 1 . Inability evaluate skin around test site due sunburn , tan , uneven skin tone , tattoo , scar , excessive hair , numerous freckle , disfiguration 2 . Used creams lotion ( ie , contain sun protection factor [ SPF ] ) test area ( ie , buttock ) within 7 day study start ( Day 1 ) 3 . Participation test irritation sensitization test involve UV exposures test area within four week study start 4 . Participation another study require biopsy ( plan test area ) within past 2 month 5 . History wound heal bloodclotting abnormality 6 . History keloid formation hypertrophic scar follow skin injury 7 . History severe reaction exposure sunlight 8 . History allergy lidocaine similar local anesthetic 9 . History allergy epinephrine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>CC-90001</keyword>
	<keyword>PHARMACOKINETICS</keyword>
	<keyword>PHARMACODYNAMICS</keyword>
	<keyword>HEALTHY SUBJECTS</keyword>
	<keyword>SINGLE DOSE</keyword>
	<keyword>MULTIPLE DOSE</keyword>
	<keyword>PUNCH BIOPSY</keyword>
</DOC>